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assessments (REAs) of pharmaceuticals are performed during the
reimbursement decision-making process. International collaboration
in the production of these assessments may prevent the duplication
of information in various jurisdictions. A ﬁrst pilot of a joint REA
(pazopanib for the treatment of renal cell carcinoma) was published
in 2011. Objective: The objective was to investigate how well the
methods used in the joint REA match the methods used in the
national/local assessments on the same topic. Methods: National/
local assessments from European jurisdictions, available in English
language, were identiﬁed through a literature search and an e-mail
request to health technology assessment organizations. Data were
abstracted from joint and national/local assessments using a
structured data abstraction form. Results were compared for differ-
ences and similarities. Results: In total, ﬁve national/local reports
were included (Belgium, England/Wales, France, The Netherlands,
and Scotland). The general methods (indication, main comparator,ee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.03.1790
@zinl.nl.
pondence to: Sarah Kleijnen, Postbus 320, 1110 AHmain end points, main trial) were similar. The details of the
assessment (e.g., exact wording of indication, additional compara-
tors, additional trials included, and method of indirect comparison),
however, varied. Despite these differences, the joint REA included
nearly all comparators, end points, trials, and methods of analysis
that were used in national/local REA reports. Conclusions: This
study has shown overlap in the methods national/local REA bodies
in Europe have chosen for a pazopanib REA for renal cell carcinoma,
except for the use and methods of indirect comparisons. Although
some additional comparators and outcomes differed between
national/local REAs, they can be captured in a comprehensive
joint REA.
Keywords: comparative effectiveness, health technology assessment,
pharmaceuticals, reimbursement.
& 2015 Published by Elsevier Inc. on behalf of International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Because of continuous rising costs in health care and budget
restraints, third-party payers often require that new, mostly
expensive pharmaceuticals have a substantial added value com-
pared with treatments that are already available [1,2]. One of the
most common claimed values is an added clinical beneﬁt and/or
better safety proﬁle. Comparing the clinical beneﬁts and harms of
a (new) technology with one or more (older) technologies used for
the same condition is commonly referred to as comparative
effectiveness in the United Stated, or relative effectiveness in Europe.
In many European jurisdictions, relative effectiveness assess-
ments (REAs) of pharmaceuticals are performed as part of the
reimbursement decision-making process [3]. These REAs need to
be performed in a limited time frame (rapid assessment) toachieve fast access for patients to new pharmaceuticals as was
laid out in the Transparency Directive (Directive 89/105/EEC) [4].
An REA is a speciﬁc element of health technology assessment
(HTA) that focuses on the clinical beneﬁt of the intervention,
whereas HTA is broader and can also include other aspects, such
as ethical, organizational, and cost-effectiveness considerations
[3].
In Europe, there is general consensus that the decision-
making process on reimbursement decisions should be under-
taken within national and local contexts in member states, also
referred to as the subsidiarity principle. This does not preclude,
however, collaboration on assessments because a clear separa-
tion of assessment and decision (or recommendation) is one of
the key principles of conducting an HTA. It may very well be
possible for the various parties to share a common assessmenton behalf of International Society for Pharmacoeconomics and
, Diemen, The Netherlands.
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ently and thus arrive at different reimbursement decisions [5].
Increased sharing of information (e.g., methods, data require-
ments, and results) across jurisdictions may increase the quality
and consistency of REAs in Europe. In addition, it may prevent
the duplication of information in various jurisdictions and save
resources accordingly [3,6].
In a multiple-country comparison, Kleijnen et al. [3] concluded
that there are more similarities than differences in the method-
ology used for REAs in European jurisdictions, indicating that a
standardized, joint production of REAs may be possible.
Workpackage 5 of Joints Action 1 (WP5JA1) of the European
network for Health Technology Assessment published a ﬁrst pilot
joint REA in 2012 [7]. WP5JA1 was a 3-year collaboration between
more than 30 European HTA organizations that was cofunded by
the European Union and had the aim to develop methods for
collaboration in the ﬁeld of REA and to test these methods [8,9].
The topic of the ﬁrst joint REA was “pazopanib for the treatment
of advanced or metastatic renal cell carcinoma.” The assessment
was coproduced by 22 HTA organizations and tested the methods
developed by the WP5JA1 as well as cross-border collaboration.
Details of the production and evaluation of the assessment are
described elsewhere [10].
Pazopanib, an antineoplastic agent that inhibits multiple
receptor tyrosine kinases, received conditional marketing author-
ization in 2011 from the European Medicines Agency [11]. The
approved therapeutic indication was for ﬁrst-line treatment of
advanced renal cell carcinoma (RCC) and for patients who have
received cytokine therapy for advanced disease previously. It was
concluded that there was a need to gain more understanding
about the beneﬁt/risk balance of pazopanib compared with other
available medicinal products for the same indication. As a result,
pazopanib received the conditional status, with the obligation to
perform a postmarketing phase III study comparing pazopanib
with sunitinib. After analysis of the results of the postmar-
keting phase III study, the conditional marketing authorization
was switched to a full marketing authorization on July 1,
2013, without changing the wording of the approved indication
[12].
Various national/local HTA reports have been produced on
pazopanib for this indication. A comparison between the joint
REA and national/local reports on the same subject could serve as
a ﬁrst indicator whether a joint REA can be informative for
national/local assessments. The objective of this study was to
investigate how well the methods used in the joint REA match
the methods used in the national/local assessments.Methods
Study Design and Selection of HTA Reports
A qualitative in-depth analysis was performed in which we
compared HTA reports on pazopanib for the treatment of RCC.
National/local reports were searched in the CRD database and
PubMed and Web sites of HTA organizations. In addition, a query
was sent to HTA organizations that were members of the Euro-
pean network for Health Technology Assessment WP5JA1 asking
whether their agency has produced an English report on pazo-
panib. In case, a report only in the native language was available,
the HTA organization was asked to translate the report into
English for inclusion in this study. Inclusion was limited to full
English HTA reports of pazopanib that were used for reimburse-
ment decision making and published before March 2012. The
joint REA was publicly available after February 2012. Therefore,
national/local reports for which the recommendations werepublished after February 2012 were excluded because reports
that were published after this date could potentially be inﬂu-
enced by the joint REA.Data Abstraction
The data were abstracted from the joint and national/local
assessment reports with a structured data abstraction form that
contained 29 open questions. The questions are presented in
Appendix Table 1 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2015.03.1790. The data were abstracted by
one researcher and double-checked by a second researcher. For
national/local reports, the abstracted data were sent to the
respective organizations by e-mail asking them to 1) validate
the abstracted data and 2) supplement the missing data that we
were not able to ﬁnd in the reports. After data abstraction was
complete, results were processed as qualitative information and
combined draft results were sent once more to the organizations
for validation. Input received as a result of the two rounds of
validation was processed accordingly.Analysis and Synthesis of Data
A selection of the gathered information is presented in this
article, with a focus on meta-data about the assessment and
the methods that were used. Data gathered on, for example, the
detailed process are not presented. The data that were selected
for this article were grouped into 1) general information about the
reports; 2) criteria included in the assessments; 3) methods used
for the assessment (including the scope, the evidence included,
and methods for assessing the evidence); and 4) outcome of the
assessments and arguments used in the recommendations. The
data were analyzed qualitatively and presented in tables. For the
comparison of the methods, the analysis was a multistep proc-
ess. First, the information included in the national/local reports
was compared, which resulted in a set of common elements and
a set of information that was not included in all national/local
reports but in at least one of them, noncommon elements.
Second, these information sets were compared with the informa-
tion in the joint REA to identify whether the methods used were
similar.
Direct comparisons were deﬁned as randomized controlled
studies (in this case placebo-controlled).
Indirect comparisons were deﬁned as comparisons of at least
two interventions for which no direct head-to-head evidence was
available.Results
General Information about the Reports
In total, HTA reports from ﬁve jurisdictions were included:
Belgium, England/Wales, France, The Netherlands, and Scotland
(see Fig. 1). One report was identiﬁed through the database search
(England/Wales), one through searches on Web sites of the HTA
organizations (Scotland), and three through the query that was
sent to HTA organizations (Belgium, France, and The Nether-
lands). The reports from Belgium, France, and The Netherlands
were translated by the respective organizations into English for
inclusion in this study. In addition, the ﬁnal version of the joint
REA (version 4), which was published on the European network
for Health Technology Assessment Web site, was included [7].
Further general information about the reports is presented in
Table 1.
Fig. 1 – Flow chart of search for national/local pazopanib assessments. HTA, health technology assessment.
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The main results are summarized in Table 1. All assessment
organizations included “efﬁcacy/effectiveness” and “safety/
harms/adverse events” in the REA. Also included in the REA in
some jurisdictions were applicability (The Netherlands and Bel-
gium), ease of use (The Netherlands and Belgium), experience
(The Netherlands), and existence of therapeutic alternatives
(France). In addition to relative effectiveness, some organizations
included other criteria such as economic consideration (cost-
effectiveness and budget impact) and/or patient or societal
considerations (e.g., equity and equality). The joint REA included
detailed information on organizational, social, ethical, and legal
considerations.
In all jurisdictions, the criteria were not explicitly weighted to
give a ﬁnal recommendation. For the Dutch report, however, it
was indicated that effectiveness and safety were usually more
relevant for the outcome compared with the other criteria. For
Belgium, it was indicated that efﬁcacy, safety, and budget impact
(and cost-effectiveness in case of claimed added value) take
precedence over the other criteria.Methods Used for the Assessment
Information included in all national/local reports, common ele-
ments, and information included in at least one of the national/
local reports, noncommon elements, are presented in Table 2. In
all reports, pazopanib was analyzed for ﬁrst-line treatment of
patients with advanced RCC. In Belgium, France, and The Nether-
lands, as well as in the joint REA, pazopanib was also analyzed
for second-line treatment of patients with RCC who were already
treated with cytokines. The indications were very similar with
some variation in exact wording. For example, “metastatic” in
addition to advanced was mentioned in the National Institute for
Health and Care Excellence (NICE) report and the joint REA (see
Table 2).
In all reports, sunitinib was chosen as a comparator for the
ﬁrst-line treatment and in case of second-line treatment sorafe-
nib was always chosen as comparator. Other comparators
included varied between jurisdictions for ﬁrst- and second-line
treatment.
In all assessments, progression-free survival (PFS) and overall
survival (OS) were included as outcomes. Other outcomes that
Table 1 – General information on pazopanib reports, criteria included in the assessments, and outcome of the assessments.
Information element BE EN/WA FR NL SC Joint assessment
General information about pazopanib reports
Reference [13] [14]* [15]† [16] [17] [7]
Assessment organization RIZIV NICE HAS CVZ‡ SMC WP5JA1
Date initiation
assessment–Date ﬁnal
recommendation
Jun 2010–Oct 2010 Jul 2010–Feb 2011 Nov 2010–
Feb 2011
July 2010–Jan 2011 Oct 2010–Feb 2011 May 2011–not applicable§
Criteria included in the assessments
Criteria evaluated as part
of the REA
Efﬁcacy, adverse
events, applicability,
ease of use
Efﬁcacy, safety Efﬁcacy, adverse
effects, therapeutic
alternatives
Effectiveness, safety,
experience, applicability,
ease of use
Comparative efﬁcacy,
comparative safety, clinical
effectiveness
Effectiveness and safety
Which other criteria have
been evaluated?
Budget impact|| Cost-effectiveness,
acceptability, appropriateness
and preference,
feasibility and impact, equity
and equality
No other criteria No other criteria|| Comparative health economic
evidence
Organizational, ethical,
social, and legal
considerations
How were the criteria
weighted?
No formal weighting
was applied
No formal weighting was
applied
Unknown No formal weighting was
applied
No formal weighting was
applied
No formal weighting was
applied
Outcome of the assessment
Final recommendation Positive Positive Negative¶ Positive Positive Not applicable
Reimbursed/funded Yes Yes Not in 2011¶ Yes Yes Not applicable
BE, Belgium; CVZ, College voor Zorgverzekeringen; EN/WA, England/Wales; EUnetHTA, European network for Health Technology Assessment; FR, France; HAS, Haute Autorité de Santé; NICE,
National Institute for Health and Care Excellence; NL, The Netherlands; SC, Scotland; REA, relative effectiveness assessment; SMC, The Scottish Medicines Consortium; RIZIV, Rijksinstituut voor
Ziekte-en Invaliditeitsverzekering; WP5JA1, Workpackage 5 of EUnetHTA Joint Action 1.
* A report of a reevaluation of pazopanib was published in EN/WA in November 2013.
† A report of a reevaluation of pazopanib was published in FR in June 2013.
‡ The institution’s name was changed to Zorginstituut Nederland (National Healthcare Institute) on April 1, 2015.
§ A joint assessment does not include a recommendation (only a conclusion about the scientiﬁc evidence) because recommendations are considered a national/local competence in Europe. The
joint report was published in December 2012.
|| In case the manufacturer would have claimed an added value, cost-effectiveness would also have been one of the criteria; however, no added value was claimed in BE and NL.
¶ The reevaluation (June 2013) changed the recommendation into positive for ﬁrst-line treatment of advanced renal cell carcinoma. For second-line treatment, the recommendation remained
negative.
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Table 2 – Methods: Common versus noncommon elements in jurisdiction-speciﬁc pazopanib assessments and comparison with joint assessment.
Information
element
Common elements:
Information included in
all jurisdiction- speciﬁc
assessments (BE, EN/WA,
FR, NL, and SC)
Noncommon elements: Other
information (not common) included in
at least one jurisdiction- speciﬁc assessment
Elements included in
joint assessment
Are common/noncommon
elements included in the
joint assessment?
Indication(s) First-line
Advanced RCC Advanced and/or metastatic RCC (EN/WA) Advanced and/or
metastatic RCC
Common: Yes
Noncommon: Yes
Second-line*
Patients with advanced RCC
who formerly have been
treated with cytokines
Patients with advanced
and/or metastatic
RCC who formerly
have been treated
with cytokines
Common: Yes
Noncommon: Not applicable
Comparators First-line
Sun Placebo (BE, FR), best supportive care (EN/WA, SC),
IFN-α (BE, EN/WA, SC), Bev þ IFN-α (BE)
Sun, IFN-α þ Bev, IFN-α,
best supportive care
Common: Yes
Noncommon: Yes
Second-line*
Sor Sun (FR, NL) Sor, best supportive care Common: Yes
Noncommon: No
Outcomes PFS, OS, RR, QOL TR/RT (BE, FR), DoR (BE, SC), AE (BE, EN/WA, SC),
FAE (BE, EN/WA, NL), SerAE (FR), WDAE (FR), ORR
(Nl), SevEA (NL)
OS, QOL, PFS, ORR, RR
(CR&PR), TTP, RT, DoR,
patient preference, AE,
WDAE, SerAE, SevAE,
and FAE
Common: Yes
Noncommon: Yes
Direct and/or
indirect
comparison
included
Direct Indirect†: BE‡, EN/WA, NL, SC Direct and indirect Common: Yes
Noncommon: Yes
Type of
analysis for
indirect
comparison
Bucher method (BE‡, SC), naive indirect
comparison (NL), not speciﬁed (EN/WA)
Bucher method Common: Not applicable
Noncommon: No, naive
indirect comparison is not
included
Studies
included
VEG105192 RCT: Lorenzo Di et al. [18] (NL) Observational:
VEG102616 (BE, EN/WA, FR, NL), VEG107769 (BE, EN/
WA, NL, SC)
RCT: VEG105192 Common: Yes
Observational:
VEG102616, VEG107769,
Hurwitz 2009 [19]
Noncommon: No, Lorenzo Di
et al. [18] (NL) was not
included in the cross-border
assessment. In addition, the
set of studies for the indirect
comparison was not identical
to the jurisdiction-speciﬁc
sets
Set of studies for indirect
comparison: 10 studies
Set of studies for indirect comparison: BE: not
speciﬁed‡; EN/WA: 8 studies; NL: 10 studies; SC: not
speciﬁed
Other: Balagula 2011 [20]§
continued on next page
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Table 2 – continued
Information
element
Common elements:
Information included in
all jurisdiction- speciﬁc
assessments (BE, EN/WA,
FR, NL, and SC)
Noncommon elements: Other
information (not common) included in
at least one jurisdiction- speciﬁc assessment
Elements included in
joint assessment
Are common/noncommon
elements included in the
joint assessment?
PFS considered
as an indicator
for OS?
No No Common: Yes
Noncommon: Not applicable
Internal
validity of the
studies
assessed?
Yes Yes Common: Yes
Noncommon: Not applicable
External
validity
addressed
Yes: EN/WA, FR, NL, SC Yes Common: Not applicable
No: BE|| Noncommon: Yes
AE, adverse event; BE, Belgium; Bev, bevacizumab; CR, complete response; DoR, duration of reponse; EN/WA, England/Wales; FAE, frequent adverse event; FR, France; NL, The Netherlands; ORR,
objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; QOL, quality of life; RCT, randomized controlled trial; RR, response rate; RT/TR, response time;
SC, Scotland; SerAE, serious adverse event; SevAE, severe adverse event; Sor, sorafenib; Sun, sunitinib; TTP, time to progression; WDAE, withdrawal due to adverse events.
* Not applicable to EN/WA and SC because second-line treatment was not assessed for these jurisdictions.
† The applicant had included an indirect comparison; however, the analysis was not considered relevant in the assessment in FR.
‡ The applicant had included an indirect comparison with sunitinib, sorafenib, IFN-α, and bevacizumab in the BE submission ﬁle. The results were presented in the BE assessment report with
the explicit caveat that it should be very cautiously interpreted and that in essence this evidence was not considered for the conclusion.
§ Systematic review and meta-analysis of the risk of hand foot skin reaction to pazopanib. Used as input for safety evaluation.
|| Although the external validity is not explicitly addressed in the assessment, it may be addressed by the reimbursement committee.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 6 3 – 6 7 2 669were reported in multiple assessments were quality of life (QOL),
response rate, adverse events, and frequent adverse events. In
the joint REA, OS, QOL, PFS, response rate, serious adverse events,
and severe adverse events were included in the main report,
whereas other outcomes were included in the appendix of the
pilot assessment.
In none of the assessments PFS was considered an indicator
for OS. England/Wales considered PFS a relevant independent
outcome because it is considered a relevant outcome for patients.
In the joint REA it was mentioned that “there are different
opinions regarding the surrogacy of PFS for OS in RCC.”
A submission ﬁle provided by the marketing authorization
holder was used as a basic source for all assessments included.
Because no template for a submission ﬁle was available yet at the
time of the assessment, the submission ﬁle used for the joint REA
was based on the submission ﬁle for NICE plus an addendum
presenting the ﬁnal OS data from the pivotal study together with
associated analyses to adjust for the effects of crossover, which
were not available yet at the time of the NICE submission.
The number of studies included in the assessments varied
between 2 (France) and 14 (joint REA). The only direct comparison
that was included in all assessments was the VEG105192 study.
This study was a double-blind, placebo-controlled randomized
controlled trial of pazopanib versus placebo. All assessments
included observational studies.
All jurisdictions used a direct comparison, and all jurisdic-
tions, except France, used an indirect comparison in their REA.
For Belgium, however, the indirect comparison performed by the
applicant was presented with the explicit caveat that it should be
very cautiously interpreted and that in essence this evidence was
not considered for the conclusion. The number of studies
included in the indirect comparison varied. The Bucher method
(adjusted indirect comparison in which the indirect comparison
of A and B is adjusted according to the results of their direct
comparisons with a common intervention) was used in at least
two indirect comparisons.
All jurisdictions assessed the internal validity of the studies
included in their assessment; however, only the Evidence Review
Group report for England/Wales and the joint REA reported the
assessment systematically. For the other assessments, the
reports refer only to the most relevant shortcomings of the data.
In all reports, except in the Belgian report, the external
validity of data was explicitly addressed to some extent. In
general, this means that one or two sentences that refer to
external validity of (some of) the studies were included. In the
joint REA, external validity was assessed and reported system-
atically. The joint REA included all methodological elements that
were identiﬁed as common elements across the national/local
reports. Furthermore, the joint REA included almost all non-
common methodological elements that were included in at least
one of the national/local reports except for one comparator for
second-line treatment (sunitinib) and one study (Lorenzo Di et al.
[18]). In addition, the set of studies for the indirect comparison
was not identical to the national/local-speciﬁc sets.
Outcome of the Assessments and Arguments Used in the
Recommendations
Except for the French authority, all organizations recommended
that pazopanib should be reimbursed/funded for the indications
that had been assessed (ﬁrst-line in Belgium, England/Wales, The
Netherlands, and Scotland and second-line in Belgium and The
Netherlands). In all jurisdictions, the reimbursement decisions
corresponded with the recommendation. For France, a reevalua-
tion was published in June 2013. It was recommended to include
pazopanib on the reimbursement list for the ﬁrst-line treatment
of advanced RCC. Inclusion for the second-line treatment ofadvanced RCC was not recommended. The joint REA did not
have a recommendation (only a conclusion about the scientiﬁc
evidence). Recommendations are considered a national/local
competence in Europe; therefore, a joint REA does not include
one.
The length of the recommendation sections varies consider-
ably between the different reports. Discussion items in multiple
assessments were the (un)certainty of the evidence from the
indirect comparison, unmet need for patients who cannot toler-
ate currently available treatments, the relevance of the OS data,
the relevance of PFS, different toxicity proﬁles, and the need for
head-to-head data. The most common argument used for a
positive recommendation was that pazopanib is considered to
be as effective as its comparators, and might have a different
and/or more favorable toxicity proﬁle than its comparators. The
most relevant argument for the negative recommendation
(France) was the uncertainty as to whether pazopanib is non-
inferior to sunitinib and may therefore result in a loss of
opportunity for the patient. It was indicated that results from
the ongoing comparative trial (pazopanib vs. sunitinib) were
necessary to address the current uncertainty around the com-
parative efﬁcacy and safety of pazopanib and sunitinib.Discussion
Some other studies have been published that compared HTA
reports for a speciﬁc topic [21–24]; however, this is the ﬁrst study
to explore differences between national/local REA reports and a
joint REA report. Moreover, this study adds to the existing
evidence base by having a detailed look at the methods used in
the REA reports.
Jurisdiction-Speciﬁc Reports versus the Joint REA
We conclude that for this topic the main methodological ele-
ments for the assessment (main comparators, end points, and
studies) on which the recommendations seem to be based are
similar between the jurisdictions except for the indirect compar-
ison. Not all jurisdictions included an indirect comparison, the
studies selected for the indirect comparison varied, and the
method for indirect comparison varied. Furthermore, there were
some differences in additional comparators (IFN-α, bevacizumab
þ IFN-α, best supportive care), additional outcomes (response
rate, duration of reponse, response time), and the additional
evidence included. In contrast to the main methodological
elements, these additional methodological elements did not
seem to have a relevant weight in the recommendation of the
jurisdictions.
The joint REA covered most methodological elements
included in the national/local reports, except for sunitinib as
second-line treatment, which was included in the Dutch and
French reports, and also different sets of studies have been used
for the indirect comparisons. The latter can partly be explained
by the fact that the indirect comparison in the joint REA included
the highest number of comparators for ﬁrst-line treatment,
which results in a wider evidence base as input for the indirect
comparison. We conclude that despite some variance in national/
local reports, the joint REA could inform the national/local
reports, due to the wide range of included comparators, the end
points, studies, and the methods of analysis. To be useful in
various national/local settings, it seems necessary to include both
direct and indirect evidence (if available) because there is var-
iance in the acceptance of indirect evidence. We also think that it
is recommendable for a joint assessment to present a relatively
high level of detail because it seems easier for national/local
organizations to summarize on the basis of an extensive joint
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 6 3 – 6 7 2670assessment compared with having to add additional details. For
example, all countries assessed the internal validity of the
studies; however, the level of detail varied. Although the internal
validity was reported systematically in only one of the national/
local reports, it is strongly recommendable to report it system-
atically in the joint REA (as currently included). This will add to
the credibility and transparency of the joint REA report, but also
maintain efﬁciency by ensuring that national/local organizations
do not have to add this level of detail themselves. Furthermore, it
is relevant to present outcomes for which different jurisdictions
may have different opinions regarding the relevance, in a neu-
trally and balanced way, leaving room for interpretation by
individual countries. This was, for example, applicable to PFS.
Some organizations considered the difference in terms of PFS
versus placebo as a patient-relevant outcome, whereas other
organizations indicated that a difference in terms of PFS is
considered patient relevant (in absence of OS data) only in case
of improved QOL. Finally, one of the comparators of the national/
local report (sunitinib for second-line treatment) was not
included in the joint REA. An extensive consultation of European
countries about possible comparators in an early stage in the
process can help to deﬁne the most appropriate comparators for
a joint assessment. In addition, it would be helpful for the
jurisdictions to include information in the joint REA report on
why possible comparators were (not) selected. For example,
sunitinib is not recommended as second-line treatment in Euro-
pean guidelines [25].
To further investigate to what extent the joint REA can serve
as a basis for national/local assessments, it may be suggested to
match the content of the single information elements. For
example, is a similar level of detail presented about the pivotal
phase three study (e.g., number of patients included, exclusion
criteria, and information on comedication)?
Comparison of Our Findings with Published Literature
Others have raised questions about the extent to which HTA
evidence requirements can be harmonized [21,24]. Trueman et al.
[24] studied assessments of a medical device (drug-eluting stent)
and concluded that the demand for evidence that is relevant to
local practice means that the core data set is relatively small and
that signiﬁcant efforts are required to generate additional data to
inform local coverage decisions. However, they also indicated
that probably the effectiveness of medical devices is more
susceptible than pharmaceuticals to differences in local practice
patterns [24]. Our study conﬁrms that pharmaceutical trials are
considered more generalizable across settings, and as a result,
there may be less need for reliance on local (registry) data. Our
study results demonstrate that there is a set of methodological
elements for pharmaceuticals that is sharable (see Table 2). In
addition, the study conﬁrms the ﬁndings of Kristensen and
Gerhardus [21] that even when an assessment is built on similar
evidence, the ﬁnal recommendations can differ. The difference
occurs because of different interpretation of the data. We were
able to identify three key differences in the interpretation of the
same evidence between jurisdictions: the relevance of PFS as a
patient-relevant outcome, the uncertainty around the evidence
(can pazopanib be considered noninferior compared with other
treatments on the basis of available evidence?), and the relevance
of the indirect comparison.
The results of the present study in general conﬁrm the results
of a previous study that we published on an investigation of 30
countries, including the countries of this case study, assessing
similarities and differences in major methodological aspects of
REA [4]. There were, however, some interesting differencesbetween the current and previous ﬁndings on the selection of
the comparator and the use of indirect comparisons. First, in the
review by Kleijnen et al. [4], only Belgium indicated that besides
other comparators, the pharmaceutical can be compared with
“whatever is used in registration trials,” which is placebo in this
case. Other countries indicated in the survey to include only the
best possible or best standard care as comparator. In our current
case study, however, results relative to placebo were mentioned
in all HTA reports included in this analysis. The results from this
analysis indicate that although the main emphasis of the HTA
reports is on comparative data, placebo-controlled data are also
very relevant, especially in the absence of comparative data.
However, it is not clear from the reports (except for England/
Wales) whether the placebo arm is considered best possible/
standard care because these patients often receive usual pallia-
tive care. Second, our previous study indicated that in Belgium,
England/Wales, France, The Netherlands, and Scotland, indirect
comparisons are included in the assessment if evidence from
head-to-head trials is not available. This case study, however,
illustrated that this is not always applicable. In this speciﬁc case,
France did not include an indirect comparison and for Belgium it
was indicated that the indirect comparison should be considered
with a lot of caution. Although indirect comparisons have
become more common in reimbursement applications for new
pharmaceuticals, many HTA organizations struggle with the
uncertainty surrounding these analyses.
The comparison of the two studies and the identiﬁed exemp-
tions illustrate that for some areas general principles for assess-
ments are challenging to deﬁne because the exact approach for
the assessment depends on the topic under assessment. For
example, the willingness to include indirect data may increase
when there are multiple comparators leading to a “network” of
evidence because it is not realistic to request comparative trials
with multiple comparators. However, when there is only one
clearly identiﬁed comparator, it becomes more realistic to
demand direct comparative data. Despite many recent efforts to
produce methodological guidelines on indirect comparisons
[26,27], further development of uniform standards is relevant
for international collaboration.
Comparison of REA Reports with Committee for Medicinal
Products for Human Use Report
There has been a discussion to which extent the REA part of HTA
reports directly after market authorization differs from the report
produced as part of the marketing authorization process, which
is the Committee for Medicinal Products for Human Use (CHMP)
assessment report in Europe [1]. Some indicate that these differ-
ences may be minor and that the additional value of REA
assessments is limited [1]. Others from HTA organizations,
however, argue that REA reports substantially differ [28] because
of different decision criteria for licensing decisions and reim-
bursement/funding decisions. Possible differences are that HTA
assessors always prefer comparative data [28], place more
emphasis on clinically relevant outcomes and health-related
QOL outcomes [1], perception of what is considered clinically
relevant, stronger emphasis by HTA assessors on external val-
idity of data, and, ﬁnally, a higher level of acceptance, by at least
some HTA assessors, of modeling and observational data [29].
When comparing the pazopanib REA reports with the CHMP risk/
beneﬁt assessment of pazopanib [30], some of these differences
are conﬁrmed. Most REA reports put more emphasis on indirect
evidence and QOL data compared with the CHMP report. In
addition, the CHMP considered the difference in terms of PFS
versus placebo as clinically relevant, whereas, as discussed
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general, however, the REA reports did not address the external
validity intensively. In addition, both the CHMP report and the
REA reports identiﬁed the lack of direct comparative data as a
relevant evidence gap. For most licensing assessments, placebo-
controlled data are sufﬁcient; however, for pazopanib, the CHMP
indicated that direct comparative data are relevant to rule out
that the use of the pharmaceutical would mean a loss of
opportunity for the patients.
It is increasingly recognized that there is considerable scope
for better, coordinated interactions between regulators and
payers [29,31]. Although the end conclusion may differ, the
examples above conﬁrm the relevance of regulator-payer inter-
action because it is very likely that they face similar evidence
dilemmas for the same compound. Further research to inves-
tigate the differences between regulatory assessments and REAs
could facilitate the interaction.
Study Limitations
The research methods used in this study have some limitations.
The data that were abstracted from national/local reports were
validated and completed by representatives from assessment
organizations, which may be prone to difference in interpretation
by the individuals. To minimize the chance, we sent queries if
difference in interpretation was suspected. In addition, ﬁve
jurisdictions were included for this study and only one topic
(pazopanib for RCC) was compared. The limited number of
national/local REA reports that could be included in this analysis
can be explained by the fact that 1) no REA report was produced
by a speciﬁc jurisdiction (before March 2012); 2) the REA report is
not publicly available; or 3) the report was not available in English
and there was not enough time or resources to translate the
report. To get a wider picture, it would be desirable to include
more jurisdictions and multiple subjects. The extent to which
these ﬁndings apply to different subjects and other jurisdictions
is still uncertain.
The pazopanib pilot joint REA was coproduced by 22 HTA
organizations, whereas more recent joint REA pilots have been
produced according to a different collaboration model involving
only a few authoring organizations (two or three) [32,33]. Despite
this change in the organizational model, we think that the
content of the pazopanib REA is similar to that of most recent
joint REAs. For this reason we think that results from this
comparison may also be indicative for the most recent joint
assessments.
By excluding national/local reports that have been published
after February 2012, we have prevented that national/local
reports could be inﬂuenced by the joint REA. This may imply,
however, that the joint REA could have been inﬂuenced by the
already available national/local reports. For example, the sub-
mission ﬁle used for the joint REA was a submission ﬁle based on
the NICE submission ﬁle. The joint REA was a collaboration of 22
countries, for which an independent assessment was done by all
the authors. Moreover, there was no overlap between the main
authors of the joint REA and the authors of the included national/
local reports. Therefore, we think that this limitation does not
have a substantial effect on the results of this study.Conclusions
This study has shown overlap in the methods national/local REA
bodies in Europe have chosen for a pazopanib REA for RCC,
especially in the evidence that was considered relevant in the
formulation of the recommendations (main comparators, out-
comes, and studies). The most relevant difference seems to bethe acceptance of and methods used for the indirect comparison.
Because of the increasing relevance of indirect evidence for
reimbursement decisions in absence of direct comparative data,
further development of uniform standards for indirect compar-
isons will be relevant for harmonization of methods. Although
inclusion of additional comparators and additional outcomes
differed between national/local REAs, because of variance in
health systems, they can be captured in a comprehensive joint
REA.
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